Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
188 hedge funds and large institutions have $2.57B invested in Audentes Therapeutics, Inc in 2019 Q4 according to their latest regulatory filings, with 86 funds opening new positions, 47 increasing their positions, 39 reducing their positions, and 46 closing their positions.
533% more funds holding in top 10
Funds holding in top 10: 3 → 19 (+16)
105% more capital invested
Capital invested by funds: $1.25B → $2.57B (+$1.32B)
87% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 46
26% more funds holding
Funds holding: 149 → 188 (+39)
21% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 39
85% less call options, than puts
Call options by funds: $12.5M | Put options by funds: $82.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$59.8M |
| 2 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$54.6M |
| 3 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$51M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$44.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$87.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$81.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$69.8M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$53.2M |
| 5 |
O
OrbiMed
New York
|
-$44.6M |
BOLD Hedge Fund Activity: Q4 2019 in Review
188 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q4 2019, worth a combined $2.57B — up 105% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new BOLD positions and 46 closed out — a net gain of 40 holders — while 47 added to existing stakes and 39 trimmed.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $59.8M. The largest seller was Redmile Group, cutting an estimated $87.2M.
- 188 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q4 2019, up from 149 in Q3 2019.
- Funds reported $2.57B of Audentes Therapeutics, Inc stock for Q4 2019, up 105% quarter-over-quarter.
- 86 funds opened new Audentes Therapeutics, Inc positions in Q4 2019 and 46 closed out, a net change of +40 holders.
- The largest Audentes Therapeutics, Inc buyer in Q4 2019 was Magnetar Financial, an estimated $59.8M added.
- The largest Audentes Therapeutics, Inc seller in Q4 2019 was Redmile Group, an estimated $87.2M sold.
Based on aggregated 13F filings for Q4 2019.